×

Message

Resource not found

News

Strong evidence for informed and timely decisions for the benefit of all patients 21-06-2022

 
Pharma_revision__2_.jpeg

ESIP-MEDEV views on the revision of the EU general pharma legislation

The upcoming proposal by the European Commission on the revision of the EU general pharmaceuticals legislation, expected by the end of 2022, intends to address shortcomings in terms of access to and availability of new treatments. Safety, quality and affordability are crucial elements for bringing effective medicines to the market with
significant benefits for patients and healthcare systems’ sustainability.

New risks, new resources and prospects for social protection in Europe 02-06-2022

 
ESIP_workshop_picture_header.jpg

ESIP workshop on the future of social protection - 28 June in Brussels

Is there a risk of erosion of social protection systems due to the ageing of the population in Europe? How can we find new resources to ensure the sustainability of our systems? What new risks should be covered by social protection? 

Appointment of Yannis Natsis as Director of ESIP 08-02-2022

 
Relay.jpg

A new chapter for ESIP

The European Social Insurance Platform (ESIP), representing statutory social security institutions from 17 Member States and Switzerland, is delighted to announce that Mr Yannis Natsis has been appointed as Director of ESIP starting from 8 February 2022. He will take over this position from Dr Christine Dawson who is retiring after 20 years of successful work and advocacy on behalf of ESIP in Brussels. 

Moving towards the revision of the EU pharma legislation 21-12-2021

 
Medical_tablets_EC_audiovisual_service4.jpg

ESIP responds to the public consultation on the revision of EU rules on pharmaceuticals

Under the Pharmaceutical Strategy for Europe, presented in November 2020, the European Commission announced the future revisions of the EU general pharmaceutical legislation as well as of the Regulations on medicines for rare and paediatric diseases. The related legislative proposals are expected by the end of 2022.

ESIP recently discussed the need to revise the general pharmaceutical legislation, with view to increasing affordability by strengthening fair competition and revising the framework for incentives.